Abstract 697P
Background
Standardised schedules for detecting testicular cancer relapse are widely employed. However, managing sequelae of treatment and empowering patients to self manage is often inconsistent within consultant-led clinics (CLC). The Empower project aimed to holistically manage patients in follow-up, whilst educating them on physical, psychological and social sequelae of treatment. This pilot of 150 patients was designed in response to local and national strategies to provide personalised stratified care.
Methods
Post-treatment patients completing 6 months of CLC surveillance were referred (with exclusions). Standard surveillance continued. Establishment and validation of the pathway involved 5 stages: 1. The Empower Team skillset was defined using an existing Experience Based Co-Design (EBCD). 2. CLC patients were surveyed on their holistic priorities. The pathway was consequentially designed; including new Scope of Practices (SOPs) addressing common unmet needs. 3. Consultations were audited. 4. Participants were re-surveyed to establish pathway effectiveness. 5. Service managers assessed impact on CLCs and implications for the wider trust.
Results
The below numbers reference stages in Methods.1. 80% agreed the skill set of a GP was suited for post treatment follow up. 2. See the table. Hypogonadism and cardiovascular pathways were created. 3. 150 patients' consultations were audited. 51.6% had a new holistic diagnosis. 100% of patients had shared care plans. 0.6% of patients required onward GP referral. 4. See the table. 5. New referrals remained stable. By 2026 a predicted 630 CLC appointments will be released. Table: 697P
CLC vs post Empower survey
Issue | % of patients who felt this was important | % of patients who felt this was addressed in CLC | % of patient s who felt this was addressed within Empower Pathway |
Lifestyle + Exercise | 80 | 9.6 | 87.5 |
Mental Health | 70 | 18.1 | 100 |
Sexual wellbeing | 50 | 13.5 | 80.5 |
Shared care decision making | N/A | 60.6 | 100 |
Conclusions
A GP/ANP testicular cancer follow up clinic complimentary runs alongside traditional CLC, leading to improved holistic outcomes. The Empower Team has qualitatively and quantitively proven it addresses patients’ unmet needs. Crucially, CLC appointments are released giving potential to scale this model to other tumour groups and Trusts.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
RM Partners.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
224P - Lung cancer scRNA-seq analyses reveal potential mechanisms causing different efficacy of target therapy and immunotherapy between EGFR 19del and L858R lung adenocarcinoma
Presenter: Hao Wang
Session: Poster session 09
225P - Nivolumab for cancer of unknown primary (CUP): Clinical efficacy and biomarker analysis from NivoCUP2 expanded access program (WJOG14620M)
Presenter: Junko Tanizaki
Session: Poster session 09
226TiP - CLEAR-Me: Interception trial to detect and clear molecular residual disease in patients with high-risk melanoma
Presenter: Erick Saldanha
Session: Poster session 09
227TiP - A phase II, open label, randomized, non-comparative cohorts study of adjuvant atezolizumab or atezolizumab plus tiragolumab in solid tumors with resectable disease with intermediate-high risk of recurrence and high tumor mutational burden (TMB-H) or microsatellite instability (MSI-H)
Presenter: Guillermo Antonio De Velasco Oria
Session: Poster session 09
228TiP - FINPROVE: The Finnish national study to facilitate patient access to targeted anti-cancer drugs
Presenter: Mika Mustonen
Session: Poster session 09
229TiP - A phase II trial of a neural network-based treatment decision support tool in patients (pts) with refractory solid organ malignancies
Presenter: Robert Walsh
Session: Poster session 09
230TiP - Exploring mechanisms of action and resistance in innovate cancer therapies: The UNLOCK program
Presenter: Beatriz Alonso de Castro
Session: Poster session 09
694P - Sequential high-dose-chemotherapy with 4 cycles paclitaxel, ifosfamide, carboplatin, etoposide (P-ICE) in relapsed/refractory male germ cell cancer: Final results with 15.8 years follow-up
Presenter: Hans Joachim Schmoll
Session: Poster session 09
695P - Assessment of the utility of CT scans in the long-term follow-up of metastatic non-seminomatous germ cell tumours (mNSGCT): The Late CT study
Presenter: Deep Chakrabarti
Session: Poster session 09
696P - Post chemotherapy retroperitoneal lymph node dissection (PC-RPLND) for metastatic pure seminoma
Presenter: David Pfister
Session: Poster session 09